A prospective case series of women with estrogen receptor-positive breast cancer: Levels of tamoxifen metabolites in controlled ovarian stimulation with high-dose tamoxifen

Human Reproduction

Volumn 28, Issue 4, 2013, Pages 953-959

  Balkenende, E M E ^a   Dahhan, T ^a   Linn, S C ^b   Jager, N G L ^c   Beijnen, J H ^c   Goddijn, M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

breast cancer; controlled ovarian stimulation; estrogen receptor; oocyte freezing; tamoxifen

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ENDOXIFEN; EPIRUBICIN; TAMOXIFEN; VINCRISTINE;

ADULT; ARTICLE; BLOOD SAMPLING; CANCER GROWTH; CANCER INHIBITION; CASE STUDY; CLINICAL EVALUATION; CRYOPRESERVATION; DRUG MEGADOSE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; NETHERLANDS; OOCYTE; OVULATION INDUCTION; PROSPECTIVE STUDY; REPRODUCTIVE PROCEDURE; SAMPLING; TANDEM MASS SPECTROMETRY;

EID: 84875613060     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/des445     Document Type: Article

References (14)

1. Barbieri RL. Female infertility (chapter 21, figure 21-8). In: Strauss JF, Barbieri RL (eds). Yen and Jaffe's Reproductive Endocrinology: Physiology, Pathophysiology and Clinical Management. Elsevier, 2009, 528.
2. Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, Jin Y, Storniolo AM, Nikoloff DM, Wu L et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 2006; 80: 61-74.
3. Borges S, Desta Z, Jin Y, Faouzi A, Robarge JD, Philips S, Nguyen A, Stearns V, Hayes D, Rae JM et al. Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol 2010; 50: 450-458.
4. Bray F, Ren JS, Masuyer E, Ferlay J. Estimates of global cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 2013; 132: 1133-1145.
5. Dowsett M, Jones A, Johnston SR, Jacobs S, Trunet P, Smith IE. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res 1995; 1: 1511-1515.
6. Hulvat MC, Jeruss JS. Maintaining fertility in young women with breast cancer. Curr Treat Options Oncol 2009; 10: 308-317.
7. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005; 97: 30-39.
8. Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW, Nikoloff DM, Hillman G, Fontecha MR, Lawrence HJ et al. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther 2011; 89: 718-725.
9. Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol 2005; 23: 4347-4353.
10. Oktay K, Hourvitz A, Sahin G, Oktem O, Safro B, Cil A, Bang H. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab 2006; 91: 3885-3890.
11. Rodriguez-Wallberg KA, Oktay K. Fertility preservation in women with breast cancer. Clin Obstet Gynecol 2010; 53: 753-762.
12. Sonmezer M, Oktay K. Fertility preservation in young women undergoing breast cancer therapy. Oncologist 2006; 11: 422-434.
13. Strauss JF, Lessey BA. The structure, function and evaluation of the female reproductive tract (chapter 9, figure 9-2). In: Strauss JF, Barbieri RL (eds). Yen and Jaffe's Reproductive Endocrinology: Physiology, Pathophysiology and Clinical Management. Elsevier, 2009, 194.
14. Teunissen SF, Jager NG, Rosing H, Schinkel AH, Schellens JH, Beijnen JH. Development and validation of a quantitative assay for the determination of tamoxifen and its five main phase I metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879: 1677-1685.